Brief: Regent Pacific Says Remains On Target To Complete Phase II Validation Study Of Fortacintm By End Of 2020
05/08/2020 12:15
Aug 5 (Reuters) - Regent Pacific Group Ltd 0575.HK :
* REGENT PACIFIC- GROUP REMAINS ON TARGET TO COMPLETE PHASE
II
VALIDATION STUDY OF FORTACINTM BY END OF 2020
Source text for Eikon: ID:nHKS9jZPKj
Further company coverage: 0575.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regent Pacific
See all newsBrief: Regent Pacific Says SenstendTM Approved By NMPA For Premature Ejaculation In China
Brief: Regent Pacific Says Deep Longevity To Launch U.S. Expansion In Q1 2026
Brief: Regent Pacific Shall Allot And Issue 63.4 Million Shares At Hk$0.485 Per Share
Brief: Regent Pacific Announces Submission Of Senstend New Drug Application To NMPA In China
Brief: Regent Pacific Enters Manufacturing And Supply Agreement For SENSTEND